Keary Dunn

Keary Dunn is a seasoned professional specialized in Food and Drug Law, Privacy, Pharmaceutical Development, and Compliance.

Having achieved a BS in Biochemical Pharmacology from the State University of New York at Buffalo and a JD with a focus on the Intellectual Property Track from George Mason University School of Law, Keary possesses a strong educational background in the legal and pharmaceutical fields.

Keary has held key positions in various prestigious organizations, currently serving as the Executive Vice President, General Counsel, and Head of Business Development at Celularity, Inc.

Prior to this role, Keary has graced the academic realm as an Adjunct Professor at St. Joseph's University - Erivan K. Haub School of Business, imparting knowledge and expertise to aspiring legal minds.

With a rich history at Novartis, Keary held several leadership roles including VP positions in US Legal, Global Drug Development, General Counsel for Cell and Gene Business Unit, among others, showcasing a deep understanding of the pharmaceutical industry.

Keary also contributed significantly to Novartis Oncology, serving as the Global Head of Ethics and Compliance and Pharmaceuticals Counsel, demonstrating a comprehensive grasp of regulatory and compliance matters within the pharmaceutical sector.

Before Novartis, Keary honed expertise in legal and regulatory affairs through roles at sanofi-aventis US, Angiotech Pharmaceuticals Inc., and Otsuka America Pharmaceutical, Inc., handling various legal aspects of corporate operations and regulatory compliance.

With a diverse professional background that includes experience as a Regulatory Project Manager at the US Food and Drug Administration and a Laboratory Technician in Neuropharmacology at Georgetown University Medical Center, Keary Dunn brings a unique blend of legal, pharmaceutical, and regulatory knowledge to the table, making her a distinguished professional in the industry.